JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Jeff Bezos Eyes $10 Billion Funding Round for AI Venture Project Prometheus 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Want to cut your energy bills? Here’s how five experts are doing it 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Dublin, May 30, 2017 -- Research and Markets has announced the addition of the "Biosimilars Market Access in Psoriatic Arthritis" report to their offering.
Tumor necrosis factor (TNF)-alpha inhibitors Enbrel, Humira, and Remicade have long held dominant positions in the psoriatic arthritis market. These market leaders, however, face patent expirations and consequent biosimilar launches.
Payers are eager to leverage these changes in the competitive landscape and enact pro-biosimilar access measures, resulting in downward pricing pressures and/or continuing market erosion for first-generation TNF-alpha inhibitors.
The rate of this erosion is likely to be gradual initially, as both physicians and payers are not likely to advocate patient switching.
Key Topics Covered:
1. Executive Summary
- US
- Inflectra carries biosimilar labeling designation, but is not interchangeable
- Physicians hesitant to use biosimilars, but understand that payers may hold sway
2. Five Major EU Markets
- Insights and strategic recommendations
- Uptake of biosimilar TNF-alpha inhibitors varies across EU markets as the EMA does not determine interchangeability
- Most physicians and payers consider biosimilars to be interchangeable, and an opportunity to reduce costs, but worries around indication extrapolation remain
- Payers use biosimilars to pressure originators on pricing
- Hospitals continue to procure both biosimilars and originators; dynamic pricing environment observed
- Biosimilars will be used as price benchmarks for pipeline agents
- Payers are unlikely to implement strong incentives to drive uptake of biosimilar infliximab due to limited use of the drug
3. Methodology
For more information about this report visit http://www.researchandmarkets.com/research/bczl5n/biosimilars
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Biosimilars and Biosuperiors
